This multi-center observational retrospective study will collect real-world clinical data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more cycles Trastuzumab Deruxtecan in Russian Federation
The aim of this trial is to explore the real-world effectiveness T-Dxd and potential predictors in Russian metastatic breast cancer patients
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Patients aged over 18 years old.
2. Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
3. Patients has received Trastuzumab Deruxtecan
4. Available medical history.
You may not be if
1. Incomplete medical history.
2. Pregnancy or breast-breeding
Clareo Health | A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients
